Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights cepharanthine as a promising candidate for COVID-19 treatment due to its antiviral activity against SARS-CoV-2 and favorable pharmacokinetic and safety profile, but reports no new clinical results.

This study found a specific T cell receptor that may be key in carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis, suggesting potential therapeutic targets.

This study reports that tofacitinib, a JAK 1/3 inhibitor, showed significant improvement in a patient with co-occurring severe alopecia totalis and lichen planus hypertrophicus, conditions that are typically resistant to treatment.

This review discusses the potential of advanced therapy medicinal products for treating vitiligo, highlighting promising results but noting affordability remains a challenge; no new clinical results were reported.

This study found that a curcumin-labeled particle-associated antiseptic penetrated deeper into hair follicles in porcine skin than particles without antiseptic.

This study suggests that geranyl acetate may offer protective, anti-inflammatory, and cytoprotective effects against PPD-induced toxicity in keratinocyte cells, indicating its potential as a plant-derived treatment.

In this case study, researchers found that treatment with sarolaner led to complete recovery from generalized demodicosis in six dogs within four weeks, resolving clinical signs without adverse reactions.

This study identified new and recurrent missense mutations in the PHGDH and PSAT1 genes, implicating them in the pathogenesis of Neu-Laxova syndrome in Chinese patients.

This study found that the combination of MT-DADMe-ImmA and MTA selectively induced apoptosis in head and neck squamous cell carcinoma cell lines FaDu and Cal27, but not in normal fibroblasts or MTAP-deficient breast cancer cells.

This review presents European guidelines for treating tinea capitis, noting systemic antifungals are essential, with griseofulvin preferred for Microsporum infections and newer antifungals viable for Trichophyton but often costlier.

This study concluded that an ointment containing pine turpentine oil, larch turpentine, and eucalyptus oil was an effective and safe treatment for folliculitis, showing improvement over placebo in lesion evolution, responder rate, and patient assessment.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

This study found that intralesional methotrexate and triamcinolone acetonide have similar efficacy for localized alopecia areata in adults, but differ in safety profiles, with methotrexate associated with hyperpigmentation and triamcinolone with atrophy.

This study developed a grooved microneedle platform enabling precise transdermal delivery of triamcinolone acetonide for alopecia areata, achieving accurate dosing by controlling groove position and drug concentration.

This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.

This study observed that topically applied RTA 408 reduced the severity of radiation-induced dermatitis in mice, with the highest dose significantly reducing and alleviating skin damage and associated inflammation.

This retrospective study evaluated the use of tofacitinib as an induction therapy for severe alopecia areata and found it promising and comparable to the standard oral mini-pulse treatment, though pulse steroids may be considered if tofacitinib response is inadequate.

TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.

This study found no significant difference in the therapeutic response to intralesional triamcinolone acetonide at concentrations of 2.5, 5, and 10 mg/mL for various dermatologic conditions.

This study reports the effective use of botulinum toxin A in treating multiple facial apocrine hidrocystomas in a 29-year-old man, a case not previously documented in English-language literature.

This article is a letter to the editor discussing potential therapeutic synergy between a wig-fixing device and tofacitinib for treating alopecia areata but reports no new clinical results.

In this case report, a 28-year-old Chinese man with severe dissecting cellulitis of the scalp experienced nodules resolution and hair regrowth after treatment with ixekizumab and tofacitinib, marking the first reported use of this drug combination for the condition.

This study found that oral JAK3 and TYK2/JAK1 inhibitors improved clinical outcomes in alopecia areata patients by reducing immune responses and enhancing hair keratin expression, with stronger effects in those with shorter disease duration.

In this study, botulinum toxin type A did not improve clinical features in patients with recalcitrant alopecia totalis or alopecia universalis over a four-month period.

PLAU and SerpinB2 affect cell death differently in various forms of leprosy and could be targets for new treatments.

This case report describes a 69-year-old woman who developed drug-induced acquired ichthyosis related to ponatinib therapy, which improved upon stopping the medication.

This study evaluated Tridax procumbens extracts for their in-vitro alpha amylase inhibitory activity compared to standard antidiabetic agents, suggesting potential benefits for diabetes management.

The researchers reported that dPGS-PCL as a carrier improved the penetration of tofacitinib in an ex-vivo human skin model compared to free tofacitinib, but did not show significant differences in inhibiting IL-6 and IL-8 during short incubation.

In this case report, a young female Indian patient with alopecia areata saw hair regrowth within 2 months of treatment with oral tofacitinib, with continued improvements over a 5-month period and no reported side effects.